RxDoctor Payments Data

Todd Florin, MD

Clinical Cardiac Electrophysiology · Aventura, FLNPI 1790741783

Payments from drug & device makers

$4,093in general payments, 2019–2025

Across 92 payments — averaging $44.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Medtronic$774
  • Impulse Dynamics (USA) Inc.$387
  • Boston Scientific$144
  • Cardiva Medical, Inc.$139
  • Amarin Pharma, Inc.$128
  • plus $579 from 15 others

What the payments were for

  • Travel & lodging$1,48436%
  • Food & beverage$2,58963%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,093 in reported general payments places this provider in the 5th percentile of 249 clinical cardiac electrophysiology providers in Florida.

See all clinical cardiac electrophysiology providers in Florida

Medicare billing

Part B allowed, 2024
$137,517
Medicare patients
610
Services billed
1,560

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban156$148,361
XareltoRivaroxaban68$73,710
EntrestoSacubitril/Valsartan27$32,287
OzempicSemaglutide16$15,136
Amiodarone Hcl67$2,782
Clonidine23$2,320
Flecainide Acetate72$1,846
Digoxin31$800
Verapamil ErVerapamil Hcl29$767
SotalolSotalol Hcl19$632
Amlodipine Besylate68$551
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide61$534
Carvedilol56$529
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$518
Atorvastatin Calcium37$515

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$91$148,361156 claims
Johnson & JohnsonXarelto$37$73,71068 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 5th percentile of 249 clinical cardiac electrophysiology providers in Florida.

Other clinical cardiac electrophysiology in Aventura

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →